Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Clin Cancer Res. 2011 Mar 18;17(8):2250–2259. doi: 10.1158/1078-0432.CCR-10-2718

Figure 5.

Figure 5

PELP1-siRNA reduce ovarian cancer cell growth in vitro and tumor progression in vivo. A, cell proliferation capacity of SKOV3ip1 and ES2 cells were analyzed after treating the cells with control or PELP1-siRNA using CellTiter-Glo assay. B, IHC analysis of PELP1 expression in tumors treated with control or PELP1-siRNA liposomes. C, number of tumor nodules, mean tumor weight (mg), and ascites volume (ml) in control siRNA-DOPC- or PELP1-siRNADOPC-treated groups (n = 8/group). Column, mean tumor weights (g); bars, SEM. *, P ≤ 0.05; **, P ≤ 0.001, t test. D, PCNA expression as a marker of proliferation, TUNEL staining as a marker of apoptosis, and MMP9 expression was analyzed by immunohistochemistry in tumors (n = 8/group) treated with control or PELP1-siRNA-DOPC; quantitation was done as described in the “Materials and Methods” section; bars, SEM. **, P < 0.001.